Skip to main content

Table 2 Characterization of leukemia patients

From: Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase

Patient

Type of leukemia

Genetic aberations

Age

Sex

Percentage of blasts during diagnosis

Peripheral blast count (×109/l)

IC50 ASNase [IU/ml]

P01

pre-B ALL

KMT2A/MLLT3

1

F

91%

161.07

0.148802

P02

interT-ALL

none detected

6

F

81%

51.03

0.014910

P03

T-ALL

none detected

20

M

92%

NA

0.000291

P04

AML M4

CBFβ-MYH11

10

F

86%

122.12

0.114985

P05

AML M1

DEK-NUP214. FLT3-ITD

17

M

85%

28.82

0.000255

P06

pro-B ALL

ETV6-RUNX1

11

F

93%

8.18

0.040462

P07

AML M4

NPM1

17

F

83%

20.75

0.037307

P08

interT-ALL

none detected

8

F

94%

68.43

0.003352

P09

pre-B ALL

IKZF1del

1

M

89%

NA

0.284902

P10

interT-ALL

none detected

15

F

91%

NA

0.023467

P11

cALL

none detected

7

M

95%

40.28

0.125948

P12

cALL

ETV6-RUNX1

5

F

95%

4.18

0.117476

P13

cALL

ETV6-RUNX1

3

M

84%

4.20

0.001058

P14

cALL

ETV6-RUNX1

10

M

89%

3.39

0.105594

P15

cALL

ETV6-RUNX1

8

F

91%

56.60

0.000184

P16

cALL

hyperdiploid

16

F

93%

26.55

0.235677

P17

cALL (partial ProB)

none detected

8

F

97%

281.30

> 0.15

P18

T/Myelo

FLT3-ITD

9

M

88%

9.90

0.000242

P19

preT-ALL

none detected

12

F

75%

139.95

> 0.15

P20

cALL

ETV6-RUNX1

4

M

96%

31.97

0.000172

P21

pre-B ALL

none detected

2

M

91%

108.98

0.147981

P22

AML M5

KMT2A/MLLTA10

1

F

83%

366.28

0.000181

P23

interT-ALL

none detected

4

M

81%

93.64

0.104566

P24

cALL

ETV6-RUNX1

8

M

96%

NA

0.005477

P25

cALL

none detected

11

F

95%

6.042

> 0.15

P26

pro-B ALL

KMT2A/AFF1 (MLL-AF4)

< 1

F

92%

404.10

0.388752

H1

Healthy B-cells

  

NA

  

Resistant

H2

Healthy mononuclear cells

  

NA

  

Resistant